{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:47:07Z","timestamp":1790801227737,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ejphar.2023.175632","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T20:30:55Z","timestamp":1677616255000},"page":"175632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Adjuvants approved for human use: What do we know and what do we need to know for designing good adjuvants?"],"prefix":"10.1016","volume":"945","author":[{"given":"C\u00e9sar","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4751-2500","authenticated-orcid":false,"given":"Manuel A.","family":"Patarroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175632_bib86","doi-asserted-by":"crossref","first-page":"121332","DOI":"10.1016\/j.lfs.2022.121332","article-title":"Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections","volume":"314","author":"Ali","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2023.175632_bib1","doi-asserted-by":"crossref","first-page":"E3788","DOI":"10.1073\/pnas.1718595115","article-title":"Plasticity in early immune evasion strategies of a bacterial pathogen","volume":"115","author":"Bernard","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2023.175632_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jama.1965.03080070025007","article-title":"A \u201cnew\u201d antigen in leukemia sera","volume":"191","author":"Blumberg","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.175632_bib3","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI38294","article-title":"CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans","volume":"119","author":"Campbell","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2023.175632_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.coi.2009.05.015","article-title":"Immune evasion by malaria parasites: a challenge for vaccine development","volume":"21","author":"Casares","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib5","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.3390\/ijerph17114140","article-title":"Observed and potential impacts of the COVID-19 pandemic on the environment","volume":"17","author":"Cheval","year":"2020","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejphar.2023.175632_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.apcsb.2015.03.003","article-title":"Recombinant lipoproteins as novel vaccines with intrinsic adjuvant","volume":"99","author":"Chong","year":"2015","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.ejphar.2023.175632_bib87","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jiph.2020.07.001","article-title":"Immune response in COVID-19: A review","volume":"13","author":"Chowdhury","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.ejphar.2023.175632_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/cid\/ciy097","article-title":"Poor immunogenicity, not vaccine strain egg adaptation, may explain the low H3N2 influenza vaccine effectiveness in 2012\u20132013","volume":"67","author":"Cobey","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2023.175632_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","article-title":"Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity","volume":"2","author":"Coccia","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ejphar.2023.175632_bib9","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1093\/infdis\/jiu345","article-title":"Global polio eradication initiative: lessons learned and legacy","volume":"210","author":"Cochi","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2023.175632_bib10","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2016.10.016","article-title":"Vaccine development: from concept to early clinical testing","volume":"34","author":"Cunningham","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2023.175632_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001804","article-title":"Pathogen evolution during vaccination campaigns","volume":"20","author":"Day","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejphar.2023.175632_bib12","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.vaccine.2008.04.052","article-title":"Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform","volume":"26","author":"Denis","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2023.175632_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2007.01.011","article-title":"Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization","volume":"363","author":"Denis","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.ejphar.2023.175632_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39475","article-title":"Central role of CD169+ lymph node resident macrophages in the adjuvanticity of the QS-21 component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175632_bib15","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113914","article-title":"Vaccine delivery systems toward lymph nodes","volume":"179","author":"Ding","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2023.175632_bib17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4161\/hv.22972","article-title":"Hypothesis driven development of new adjuvants: short peptides as immunomodulators","volume":"9","author":"Dong","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.ejphar.2023.175632_bib18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2023.175632_bib19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.175632_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine development for emerging infectious diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.175632_bib21","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nm.2306","article-title":"Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity","volume":"17","author":"Flach","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2023.175632_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrg2703","article-title":"Origin and evolution of the adaptive immune system: genetic events and selective pressures","volume":"11","author":"Flajnik","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ejphar.2023.175632_bib23","author":"Food and Drug Administration"},{"key":"10.1016\/j.ejphar.2023.175632_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/14760584.2013.811188","article-title":"An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants","volume":"12","author":"Fox","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejphar.2023.175632_bib25","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/eji.200838549","article-title":"The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity","volume":"38","author":"Franchi","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11591760-000000000-00000","article-title":"Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach","volume":"25","author":"Garon","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2023.175632_bib27","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1084\/jem.20060401","article-title":"Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation","volume":"203","author":"Guiducci","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2023.175632_bib28","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/bs.ai.2016.11.001","article-title":"Chapter four - nucleic acid immunity","author":"Hartmann","year":"2017"},{"key":"10.1016\/j.ejphar.2023.175632_bib29","series-title":"Bioconjugate Techniques","first-page":"839","article-title":"Chapter 19 - vaccines and immunogen conjugates","author":"Hermanson","year":"2013"},{"key":"10.1016\/j.ejphar.2023.175632_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12016-019-08740-1","article-title":"The innate part of the adaptive immune system","volume":"58","author":"Hillion","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167488","article-title":"Cell-based systems biology analysis of human AS03-adjuvanted H5N1 avian influenza vaccine responses: A phase I randomized controlled trial","volume":"12","author":"Howard","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175632_bib32","doi-asserted-by":"crossref","first-page":"W24","DOI":"10.1093\/nar\/gkx346","article-title":"BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes","volume":"45","author":"Jespersen","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2023.175632_bib33","doi-asserted-by":"crossref","first-page":"12878","DOI":"10.1073\/pnas.1717159115","article-title":"Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance","volume":"115","author":"Kennedy","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2023.175632_bib34","article-title":"Why does drug resistance readily evolve but vaccine resistance does not?","volume":"284","author":"Kennedy","year":"2017","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.ejphar.2023.175632_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52687","article-title":"Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway","volume":"9","author":"Kim","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ejphar.2023.175632_bib36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3349\/ymj.2016.57.1.5","article-title":"NOD-like receptors in infection, immunity, and diseases","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.ejphar.2023.175632_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejphar.2023.175632_bib38","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2023.175632_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejphar.2023.175632_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4110\/in.2015.15.2.51","article-title":"Recent advances of vaccine adjuvants for infectious diseases","volume":"15","author":"Lee","year":"2015","journal-title":"Immune Netw."},{"key":"10.1016\/j.ejphar.2023.175632_bib42","series-title":"Vaccine Potentiation by Combination Adjuvants","author":"Levast","year":"2014"},{"key":"10.1016\/j.ejphar.2023.175632_bib43","first-page":"601","article-title":"Emerging adjuvants for cancer immunotherapy","volume":"1","author":"Li","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejphar.2023.175632_bib44","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/bph.14816","article-title":"Natural compounds as potential adjuvants to cancer therapy: preclinical evidence","volume":"177","author":"Lin","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175632_bib45","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0264-410X(99)00232-7","article-title":"Glycoprotein conjugate vaccines","volume":"17","author":"Lindberg","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2023.175632_bib46","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants - in retrospect and prospect","volume":"22","author":"Lindblad","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2023.175632_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/pharmaceutics13020142","article-title":"TLR agonists as vaccine adjuvants targeting cancer and infectious diseases","volume":"13","author":"Luchner","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2023.175632_bib48","article-title":"A comparison of cancer vaccine adjuvants in clinical trials","volume":"34","author":"Marriott","year":"2023","journal-title":"Cancer Treat Res. Commun."},{"key":"10.1016\/j.ejphar.2023.175632_bib49","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14712598.2.8.895","article-title":"Reverse vaccinology: a genome-based approach for vaccine development","volume":"2","author":"Masignani","year":"2002","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2023.175632_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: interferon induction by double-stranded RNA including poly(I:C)","author":"Matsumoto","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2023.175632_bib51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/mi.2014.111","article-title":"Cholera toxin adjuvant promotes a balanced Th1\/Th2\/Th17 response independently of IL-12 and IL-17 by acting on Gs\u03b1 in CD11b+ DCs","volume":"8","author":"Mattsson","year":"2014","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101533","article-title":"Mutations of SARS-CoV-2 spike protein: implications on immune evasion and vaccine-induced immunity","volume":"55","author":"Mengist","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib55","first-page":"430","article-title":"Engineered immunogen binding to alum adjuvant enhances humoral immunity","volume":"26","author":"Moyer","year":"2020","journal-title":"Nat. Med. (N. Y., NY, U. S.)"},{"key":"10.1016\/j.ejphar.2023.175632_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.chom.2018.12.006","article-title":"Innate and adaptive immune memory: an evolutionary continuum in the host's response to pathogens","volume":"25","author":"Netea","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejphar.2023.175632_bib57","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O'Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2023.175632_bib58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/eji.201747150","article-title":"The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses","volume":"48","author":"Oleszycka","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib59","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1093\/emboj\/20.16.4443","article-title":"HBV infection of cell culture: evidence for multivalent and cooperative attachment","volume":"20","author":"Paran","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2023.175632_bib60","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2023.175632_bib61","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/bioengineering8110155","article-title":"Novel vaccine adjuvants as key tools for improving pandemic preparedness","volume":"8","author":"Pogostin","year":"2021","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.ejphar.2023.175632_bib62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2023.175632_bib63","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2023.175632_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep16719","article-title":"GPRC6A mediates Alum-induced Nlrp3 inflammasome activation but limits Th2 type antibody responses","volume":"5","author":"Quandt","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2023.175632_bib65","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2023.175632_bib66","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2023.175632_bib67","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"SAVE Proc."},{"key":"10.1016\/j.ejphar.2023.175632_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031925","article-title":"Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites","volume":"7","author":"Rioux","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175632_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.08.004","article-title":"The current status of COVID-19 vaccines. A scoping review","volume":"27","author":"Rueda-Fern\u00e1ndez","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2023.175632_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228381","article-title":"The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins","volume":"15","author":"Safar","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.175632_bib71","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s11095-014-1419-y","article-title":"Biomaterials for nanoparticle vaccine delivery systems","volume":"31","author":"Sahdev","year":"2014","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejphar.2023.175632_bib72","article-title":"Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators","author":"Schmidt","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2023.175632_bib73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.provac.2011.10.008","article-title":"Human vaccines and their importance to public health","volume":"5","author":"Schuchat","year":"2011","journal-title":"Procedia Vaccinol."},{"key":"10.1016\/j.ejphar.2023.175632_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.125854","article-title":"Co-assembled and self-delivered epitope\/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy","volume":"399","author":"Shi","year":"2020","journal-title":"J. Chem. Eng."},{"key":"10.1016\/j.ejphar.2023.175632_bib75","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/vaccines7020038","article-title":"Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines","volume":"7","author":"Shrestha","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejphar.2023.175632_bib88","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clnu.2023.01.001","article-title":"Influence of biotic interventions on the immune response to vaccines in young and older adults","volume":"42","author":"Spacova","year":"2023","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejphar.2023.175632_bib76","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.1840010502","article-title":"A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report","volume":"1","author":"Szmuness","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2023.175632_bib77","series-title":"Vaccines for Veterinarians","first-page":"75","article-title":"Chapter 7 - adjuvants and adjuvanticity","author":"Tizard","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175632_bib78","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.2174\/092986711795933740","article-title":"Aluminum vaccine adjuvants: are they safe?","volume":"18","author":"Tomljenovic","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175632_bib79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2023.175632_bib80","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/vaccines8010128","article-title":"Better adjuvants for better vaccines: progress in adjuvant delivery systems, modifications, and adjuvant\u2013antigen codelivery","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ejphar.2023.175632_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413397","article-title":"Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases","volume":"22","author":"Wicherska\u2010paw\u0142owska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.175632_bib82","series-title":"World Health Statistics","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejphar.2023.175632_bib83","series-title":"Immunization, Vaccines and Biologicals","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejphar.2023.175632_bib84","series-title":"Antibiotic Resistance","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejphar.2023.175632_bib85","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/JLB.4MR0220-446R","article-title":"Innate immune memory of tissue-resident macrophages and trained innate immunity: Re-vamping vaccine concept and strategies","volume":"108","author":"Xing","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejphar.2023.175632_bib89","first-page":"S2090","article-title":"Inflammasomes cross-talk with lymphocytes to connect the innate and adaptive immune response","volume":"23","author":"Zhang","year":"2023","journal-title":"J. Adv. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923001437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:16:17Z","timestamp":1757978177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923001437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":89,"alternative-id":["S0014299923001437"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175632","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvants approved for human use: What do we know and what do we need to know for designing good adjuvants?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175632"}}